ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,232.04
-0.37%
Dow Jones
38,528.84
-0.11%
Gold vs US Dollar
2,324.775
-1.11%
Brent Oil
77.695
-0.57%
Bitcoin
70,820.49
2.93%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. ZyVersa Therapeutics Inc (ZVSA) Share Price

ZVSA ZyVersa Therapeutics Inc

4.917
0.057 (1.17%)
Last Updated: 17:07:42
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 ZyVersa Therapeutics Inc NASDAQ:ZVSA NASDAQ Common Stock  
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   0.057 1.17 4.917 4.84 4.94 5.2015 4.89 4.9 53,549 16:07:42   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Pharmaceutical Preparations  -106.25M -85.4550 -0.26 27.97M
 Type  Size  Price  Time  Units 
 9 1 4.8401 16:11:30 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore ZVSA News
15/05/202413:35GLOBEZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update
15/05/202413:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
15/05/202413:25EDGAR2Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
14/05/202412:57GLOBEZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention
29/04/202412:57GLOBEZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease
04/04/202412:57GLOBEZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes
25/03/202412:17GLOBEZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Period
Draw mode
Data Downloads for ZVSA

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest ZyVersa Therapeutics Inc Articles